Do immune inflammatory markers correlate with anal dysplasia and anal cancer risk in patients living with HIV?
- PMID: 35332364
- DOI: 10.1007/s00384-022-04123-9
Do immune inflammatory markers correlate with anal dysplasia and anal cancer risk in patients living with HIV?
Abstract
Purpose: People living with HIV (PLWH) are at an elevated risk for developing anal cancer. As screening is invasive, markers predicting those at highest risk for anal cancer could guide individualized screening. Neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), and prognostic nutritional index (PNI) are surrogate inflammatory/immune markers known to correlate with cancer outcomes. This study aims to assess whether these markers correlate with anal cancer risk in PLWH.
Methods: This is a retrospective single-institution cohort study of PLWH at a single academic medical center who were diagnosed with or screened for anal dysplasia between 2001 and 2019. Aforementioned markers collected within one year of diagnosis were recorded. Regression modeling was used to estimate odds of anal cancer. Receiver operating characteristic analysis was utilized to determine optimal cutoff for screening values.
Results: Five-hundred-fourteen patients were included. NLR and PNI were significantly associated with cancer risk on univariate (p = 0.03, p = 0.001) and multivariate analyses (p = 0.03, p = 0.01). NLR increased across all grades of dysplasia. PLR was not associated with cancer risk. A NLR of ≥ 1.64 can be utilized to capture 76% of cancer patients in our cohort.
Conclusions: NLR values in patients living with HIV correlate with risk of anal cancer and increasing grades of dysplasia. A cutoff NLR of ≥ 1.64 can be used to help capture those at risk. NLR is a promising marker of risk of anal cancer and progression of anal dysplasia in patients with HIV infection and could be used to risk-stratify screening and surveillance intervals.
Keywords: Anal cancer; Anal dysplasia; HIV; Neutrophil lymphocyte ratio; Prognostic nutritional index.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Ryan DP, Compton CC, Mayer RJ (2000) Carcinoma of the anal canal. N Engl J Med 342:792–800. https://doi.org/10.1056/NEJM200003163421107 - DOI - PubMed
-
- Koskan AM, Brennhofer SA, Helitzer DL (2019) Screening for anal cancer precursors among patients living with HIV in the absence of national guidelines: practitioners’ perspectives. Cancer Causes Control 30:989–996. https://doi.org/10.1007/s10552-019-01209-8 - DOI - PubMed
-
- Apaydin KZ, Fontenot HB, Shtasel DL, Mayer KH, Keuroghlian AS (2018) Primary care provider practices and perceptions regarding HPV vaccination and anal cancer screening at a boston community health center. J Community Health 43:792–801. https://doi.org/10.1007/s10900-018-0486-0 - DOI - PubMed - PMC
-
- Templeton AJ, McNamara MG, Šeruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106:dju124. https://doi.org/10.1093/jnci/dju124
-
- Sun K, Chen S, Xu J, Li G, He Y (2014) The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 140:1537–1549. https://doi.org/10.1007/s00432-014-1714-3 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
